Trial Comparing Behavioral Activation to Relapse Prevention for Veterans with AUD and PTSD
This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.
Phase III
Mental Health / Behavioral Interventions
Status
Active
Sponsor
U.S. military veterans
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.
Why it matters
This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.
What changed
Trial Update
Analysis
This clinical trial aims to adapt and evaluate Behavioral Activation for veterans with co-occurring AUD and PTSD against Relapse Prevention.
This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.
Monitor results on feasibility and acceptability of Behavioral Activation, as well as any significant outcomes related to AUD/PTSD recovery.
Related companies & assets
Sources & Humanexa intelligence
Source links
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.